AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02968771 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Study NCT01828567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making with a Prevention Coach
Description: A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
Study NCT02226757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-trastzumab
Description: Trastuzumab~* Dose:~  * First dose: 4 mg/kg IV~ * Subsequent doses: 2 mg/kg every week IV.~* The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab
Study NCT03293407 — intervention group
Intervention type: DRUG
Intervention: Iloprost (Ventavis, BAYQ6256)
Description: Using Breelib device
Study NCT03293407 — intervention group
Intervention type: DEVICE
Intervention: Breelib nebulizer
Description: Used for inhalation of Ventavis
Study NCT00148642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver salts coated endotracheal tube
Description: intubation with silver coated tube
Study NCT00148642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: uncoated endotracheal tube
Description: intubation
Study NCT02573090 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive resin based fissure sealing
Description: The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
Study NCT02573090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive resin based restoration
Description: The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
Study NCT02637609 — intervention group
Intervention type: OTHER
Intervention: Likert Scale
Description: Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
Study NCT02637609 — intervention group
Intervention type: OTHER
Intervention: Best-Worst Scaling (Case 1)
Description: Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
Study NCT01909986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ONO-4053
Description: Single dose \[14C\]ONO-4053
Study NCT04235088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somatosensory intensive intervention
Description: The intensive somato-sensory intervention will take place during 3 weeks, 5 days per week, for 2 hours per day (30 hours of practice). During the week-ends, some somato-sensory written activities will be explained and handed to each family (6 hours of practice) Therapy sessions will be carried out in groups and each child will have his or her own therapist in charge of his or her treatment along the whole intervention. A daily check-list, design for that purpose, will be used by the therapist in order to register the gradually increased complexity of the activities and individual progression. The principal investigator will supervise all the interventions in order to assure their uniformity, adjusting the somato-sensory training protocol to the individual needs of each subject.
Study NCT03994718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The music therapist will work with subjects for up to 60 minutes each session.
Study NCT03994718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual arts intervention
Description: The visual artist will work with subjects for up to 60 minutes each session.
Study NCT03994718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative writing intervention
Description: The creative writer will work with subjects for up to 60 minutes each session.
Study NCT01290562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: One or more high dose(s) of radiation to treat the tumour.
Study NCT03401125 — intervention group
Intervention type: OTHER
Intervention: Medical file data collection
Description: The information described in the 'outcome measures' section will be collected from the medical files of the patients.
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 90 days)
Description: 90 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 180 days)
Description: 180 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Dabigatran: extended treatment (e.g at least 270 days)
Description: 270 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 90 days)
Description: 90 days
Study NCT03182478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rothbaum protocol in individual format
Description: 8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
Study NCT03182478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rothbaum protocol in group format
Description: 8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
Study NCT01181297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively Hydrolyzed Formula with a Probiotic
Study NCT01181297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Extensively Hydrolyzed Formula without a Probiotic
Study NCT01600105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfusion MRI
Description: 1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
Study NCT05267938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthetic
Description: The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 180 days)
Description: 180 days
Study NCT05267938 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical Anesthetic
Description: The topical anesthetic used in this experimental is EMLA® after the pre-treatment of the palatal mucosa
Study NCT05267938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
Study NCT05267938 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Local anesthetic
Description: After the pre-treatment with microneedles and the use of topical anesthetic, the needle and injection of local anesthetic was inserted and pain was evaluated
Study NCT04559997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise+FU
Description: 6 years intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
Study NCT04559997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator group Exercise
Description: After 3 weeks of intensive therapy, we withdrew treatment and monitored their condition for 6 years and received only hospital base treatment
Study NCT01878240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR without coils embolization/ Coils embolization during EVAR
Study NCT01878240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVAR without coils embolization/ Coils embolization during EVAR
Study NCT02859454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
Study NCT03435445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online platform group
Description: The online platform has social network, gamification and short-text sessions.
Study NCT03435445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online dietitian coaching
Description: Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Apixaban: extended treatment (e.g at least 270 days)
Description: 270 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 90 days)
Description: 90 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 180 days)
Description: 180 days
Study NCT03271450 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban: extended treatment (e.g at least 270 days)
Description: 270 days
Study NCT03435445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Minimal intervention with four videos with diet, physical activity and behavior change recommendations
Study NCT00673803 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery with implantation of an IOL
Study NCT03785808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy (low-carb)
Description: Receive dietary guidelines and recipes and consume a low-carbohydrate diet
Study NCT03785808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Special Diet Therapy (low-fat)
Description: Receive dietary guidelines and recipes and consume a low-fat diet
Study NCT03785808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special Diet Therapy (USDA control)
Description: Receive dietary guidelines and recipes and consume USDA control diet
Study NCT05015244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3T (Tesla) Magnetic Resonance Imaging (MRI)
Description: Neurological evaluation using MRI and neuropsychological tests
Study NCT00574132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Description: infusion every 13 weeks for a total of 6 infusions
Study NCT00574132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: given by infusion every 13 weeks for a total of 6 infusions.
Study NCT00574132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 m/kg
Description: infusion every 13 weeks for a total of 6 infusions
Study NCT02912910 — intervention group
Intervention type: OTHER
Intervention: Nifedipine
Description: patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
Study NCT02912910 — intervention group
Intervention type: OTHER
Intervention: Labetalol
Description: patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
Study NCT00905697 — intervention group
Intervention type: PROCEDURE
Intervention: Living donor lung transplantation
Description: Living donor lung transplantation
Study NCT00725569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bellis perennis and Staphysagria (C6)
Description: homeopathic remedy
Study NCT00725569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bellis perennis and Staphysagria (C30)
Description: Homeopathic Remedy
Study NCT00725569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo remedy, identical in size, shape and taste to treatment remedies
Study NCT04922437 — intervention group
Intervention type: PROCEDURE
Intervention: Native bladder implantation
Description: Continent catheterizable channel implanted in the detrusor of the native bladder
Study NCT04922437 — intervention group
Intervention type: PROCEDURE
Intervention: Enterocystoplasty implantation
Description: Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
Study NCT01778218 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Description: An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
Study NCT04672993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urine collection device for men
Description: Use of urine collection device for men
Study NCT00836485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen 4.0% Patch
Description: This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
Study NCT00836485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control is a placebo patch that contains only the inactive ingredients of ketotifen.
Study NCT00836485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.2%
Description: 1 gtt/eye on two separate occasions
Study NCT00836485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: 1 gtt/eye on two separate occasions
Study NCT01278979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Objective measurements of perineal tears with Peri-Rule
Description: Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus.
Study NCT01278979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual and digital assessment
Description: Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
Study NCT02650167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Colostrum feeding
Study NCT02650167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: formula for preterm infants
Study NCT01641081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate in the Pressair DPI, Low Dose
Description: Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
Study NCT01641081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate in the Pressair DPI, High Dose
Description: Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
Study NCT01641081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer, Low Dose
Description: Foradil Aerolizer 12 micrograms, twice a day for 14 days
Study NCT01641081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer, High Dose
Description: Foradil Aerolizer 24 micrograms, twice per day for 14 days
Study NCT01641081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in the Pressair for 14 days
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg Tablet
Description: Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate 10Mg Tablet
Description: 1-2 tablets 2 times a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isosorbide Dinitrate 10Mg Tablet
Description: 1-2 tablets 2 times a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 75Mg Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetylsalicylic Acid 75Mg Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate 2.5 MG Oral Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bisoprolol Fumarate 2.5 MG Oral Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium 20 MG Oral Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin Calcium 20 MG Oral Tablet
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 5 MG
Description: 1 tablet per a day
Study NCT03011775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril 5 MG
Description: 1 tablet per a day
Study NCT02035930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexmedetomidine
Study NCT01147367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 month physical activity intervention
Description: 3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
Study NCT05553262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support as described under 'Arm description'.
Study NCT02283840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT01603706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echo guided implantation group
Description: Lead placement according echo strain imaging result
Study NCT03850171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
Study NCT01149525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 2g oral solution , twice per day (morning/evening), during 3 months
Study NCT01149525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution, twice per day (morning/evening), during 3 months
Study NCT01720472 — intervention group
Intervention type: GENETIC
Intervention: Biomarker studies
Study NCT01452191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Briefing Plus facilitation
Description: Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
Study NCT01452191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Briefing
Description: Children's centres will receive the Injury Prevention Briefing only.
Study NCT04092439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Watermelon Juice
Description: 100% Watermelon Juice
Study NCT01863901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Cryo-Touch III device